\nSTAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer\u00ae<\/sup> Lenses (EVO ICL\u2122) for vision correction, issued the following statement:<\/p>\n
\n\u201cThe merger with Alcon provides STAAR stockholders with compelling, premium cash value, including a 51% premium to the closing price of STAAR common stock on August 4, 2025 (the day prior to the agreement being announced) and a 59% premium to STAAR\u2019s 90-day Volume Weighted Average Price (VWAP) as of that date.<\/p>\n
\nWe believe the $28 per share cash value provided by the Alcon agreement exceeds what STAAR could achieve on a standalone basis in the foreseeable future, particularly given STAAR\u2019s lower growth rate and the resulting impact on its valuation, and the substantial competitive and macro challenges in the markets STAAR serves. STAAR is heavily exposed to China, which faces significant economic uncertainty and where sales trends have been declining despite actions taken by the Company. Notably, STAAR\u2019s common stock closed at $18.49 per share on the trading day prior to the announcement of the Alcon agreement.<\/p>\n
\nThe merger agreement includes provisions that are highly favorable to STAAR stockholders and were extensively negotiated by the Company to further its value-maximizing objective.<\/p>\n
\nWe look forward to engaging with our stockholders on the merits of the Alcon merger and why the STAAR Board of Directors unanimously believes it is in the best interest of all STAAR stockholders.\u201d<\/p>\n
About STAAR Surgical<\/span><\/b><\/p>\n \nSTAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer\u00ae<\/sup> Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL\u2019s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye\u2019s natural crystalline lens. Its EVO ICL\u2122 product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com<\/a>. To learn more about STAAR, visit www.staar.com<\/a>.<\/p>\n Additional Information About the Merger and Where to Find It<\/span><\/b><\/p>\n \nThis communication relates to the proposed transaction involving STAAR. In connection with the proposed transaction, STAAR has filed relevant materials with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), including STAAR\u2019s preliminary proxy statement on Schedule 14A, and will file a definitive proxy statement on Schedule 14A (the \u201cProxy Statement\u201d). This communication is not a substitute for the Proxy Statement or any other document that STAAR may file with the SEC or send to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF STAAR ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC\u2019s website, www.sec.gov<\/a>, or by visiting STAAR\u2019s investor relations website, https:\/\/investors.staar.com<\/a>.<\/p>\n No Offer or Solicitation<\/span><\/b><\/p>\n \nThis communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.<\/p>\n Participants in the Solicitation<\/span><\/b><\/p>\n \nUnder SEC rules, STAAR and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the holders of STAAR\u2019s common stock in connection with the proposed transaction. Information about the directors and executive officers of STAAR and their ownership of STAAR\u2019s common stock is set forth in the definitive proxy statement for STAAR\u2019s 2025 Annual Meeting of Stockholders (the \u201cAnnual Proxy Statement\u201d), which was filed with the SEC on April 24, 2025 (and which is available at https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/0000718937\/000095017025058174\/staa-20250424.htm<\/a>), including the sections captioned \u201cCompensation of Directors,\u201d \u201cInformation Regarding Executive Officers\u201d and \u201cSecurity Ownership of Principal Shareholders and Management,\u201d or its Annual Report on Form 10-K for the year ended December 27, 2024, which was filed with the SEC on February 21, 2025 (and which is available at https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/0000718937\/000095017025024813\/staa-20241227.htm<\/a>), and in other documents filed by STAAR with the SEC. To the extent holdings of such participants in STAAR\u2019s securities have changed since the amounts described in the Annual Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC by STAAR\u2019s directors and executive officers. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available.<\/p>\n Forward-Looking Statements<\/span><\/b><\/p>\n \nThe information covered by this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cmay,\u201d and similar terms. All statements in this communication that are not statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement between the parties to the proposed transaction or extend the anticipated timetable for completion of the proposed transaction; (2) the failure to obtain approval of the proposed transaction from STAAR\u2019s stockholders; (3) the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4) risks related to disruption of management\u2019s attention from STAAR\u2019s ongoing business operations due to the proposed transaction; (5) the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6) the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8) the possibility that STAAR\u2019s stock price may decline significantly if the proposed transaction is not consummated; and (9) other important factors set forth in STAAR\u2019s Annual Report on Form 10-K for the year ended December 27, 2024 under the caption \u201cRisk Factors,\u201d as any such factors may be updated from time to time in STAAR\u2019s other filings with the SEC.<\/p>\n \nForward-looking statements speak only as of the date they are made and, except as may be required under applicable law, STAAR undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250902743981\/en\/<\/a><\/span><\/p>\n \nNiko Liu, CFA \nConnie Johnson KEYWORDS:<\/b> United States North America California<\/p>\n INDUSTRY KEYWORDS:<\/b> Optical Health Surgery Medical Devices<\/p>\n<\/p>\n
\n
United States: 626-303-7902 ext 3023
\n
Hong Kong: +852-6092-5076
\n
nliu@staar.com
\n<\/a>
investorrelations@staar.com<\/a><\/p>\n
\n
+1 626 303 7902 (x-2207)
\n
cjohnson@staar.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250902743981\/en\/683092\/3\/STAAR_Surgical_Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n